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Abstract 
Background: Borderline Personality Disorder (BPD) is one of the most frequent, most 
debilitating and lethal mental conditions and is associated with a serious burden of disease. 
Treatment for patients with BPD involves structured psychotherapy, and may involve brief 
psychiatric treatment as first-line intervention. No controlled study has assessed the 
effectiveness of such brief intervention. Whereas most psychotherapy studies with patients 
with BPD focus on the effectiveness of the intervention, we still lack an understanding of how 
and why these effects are produced from a patient process perspective. It is therefore of 
utmost importance to study the treatment-underlying mechanisms of change. The present 
study plans to apply novel measurement methods for assessing change in two central 
psychobiological processes in BPD: emotion and socio-cognitive processing. The study uses 
theory-driven and ecologically valid experimental tasks which take as anchor the patient’s 
individual experience, by integrating methodology from psychotherapy process and 
neurofunctional imagery research. 
Methods: The present two-arm randomized controlled study aims at testing the effects (i.e., 
symptom reduction) and the underlying mechanisms of change associated with a brief 
psychiatric treatment (10 sessions over 4 months), compared with treatment as usual. 
Participants (N = 80 patients with BPD) undergo assessments at four points (intake, 2 
months, discharge, and 12 month follow-up). In addition to symptom measures, individua ls 
undergo a two-step assessment for the potential mechanisms of change (i.e., emotion and 
socio-cognitive processing): a) behavioural and b) (for a sub-sample) neurofunctional. We 
hypothesize that change in the mechanisms explains the treatment effects. 
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Discussion: The present study uses an easy-to-implement treatment of BPD, as well as a 
sophisticated assessment procedure to demonstrate the critical role of psychobiological 
change in emotion and socio-cognitive processing in brief treatments. It will help increase the 
effectiveness of brief treatment for BPD and help diminish the societal burden of disease 
related with BPD, in these early stages of treatment. 
Trial registration {2}: Clinical Trials NCT03717818 (date of registration of Abstract October 
24th, 2018). Protocol version {3} number 2 from February 9th, 2018. 
Keywords: Psychiatric Treatment; Randomized Controlled Trial; Mechanisms of Change; 
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Background and Rationale {6a} 
Borderline Personality Disorder (BPD) is one of the most prevalent mental disorders 
with 2-3% in the general population. Direct societal costs are related with frequent emergency 
service use, intense use of inpatient and outpatient treatments, indirect societal costs stemming 
from prolonged sick leaves, abusive street drug consumption, intra-familiar abuse and neglect 
and in some cases legal costs (1, 2).  
Psychological treatments are considered first-line for problems related with 
Personality Disorders (3-6). Whereas there are several theoretical accounts on how these 
effects are produced, there is a paucity of systematic empirical research focusing on 
mechanisms of change in treatments of PDs (7-13), aiming at empirically explaining how 
treatments work and, ultimately, increasing the treatment’s effectiveness. Such an empirical 
understanding would be particularly useful at the beginning of treatment: a better knowledge 
of the determinants of initial symptom alleviation in psychological treatment would allow to 
deliver even more potent treatments for these patients from the very first session on, and to 
prevent some of the long-term consequences of the disorder.  
The objective of the present study is to explain early symptom change in patients with 
borderline personality disorder undergoing a brief psychiatric treatment that is consistent with 
the international and national treatment guidelines (3, 14). We assume that symptom change is 
the result of a complex interplay between changing central process characteristics of the 
patient – assessed from an integrated neuro-behavioral perspective – and the moment-by-
moment responsive adjustment by the therapist to them. The present trial examines two 
patient-related mechanisms of change in treatments of BPD: (1) emotion processing (2) 
change in socio-cognitive processing. By aiming at discovering the underlying “laws of 
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change” in patients undergoing brief treatments for BPD, such research may help increase the 
effectiveness of any bona fide therapy approach from the very first session on and thus may 
help decrease direct and indirect societal costs related with BPD. 
In order to achieve this, we aim at studying a specific brief guideline-based 
intervention for BPD. In addition to the structured psychotherapy models validated for the 
treatment of Borderline Personality Disorder (e.g., Dialectical-Behavior Therapy, 
Mentalization-Based Therapy, Transference-Focused Psychotherapy), the past 10 years have 
witnessed the emergence of psychiatric approaches to the treatment of BPD (15, 16). In a 
randomized controlled trial, McMain and colleagues (17, 18) have tested the efficacy of a 1-
year long Dialectical-Behavior treatment program to an equally long General Psychiatric 
Management GPM (19, 20).The results were somewhat unexpected, showing that both 
treatments did equally well on all outcome indices and most process characteristics, including 
symptom relief until 2 years after the end of treatment. Bateman and Fonagy (2009) used a 
similar type of psychiatric approach in which they found consistent results with regard to the 
comparison with mentalization-based treatment (MBT) (21). These emerging studies may 
suggest that for at least the first phase of treatment of patients with BPD, it might be sufficient 
to offer a psychiatric intervention which is easily learnable; as such, we increase general 
access to mental health intervention for a large amount of patients with BPD (22, 23). Such 
new health care models have been advocated within the stepped-care literature for BPD (24-
26). 
To date, no study has examined such a brief guideline-based psychiatric intervention, 
together with its explanatory mechanisms of change for outcome, compared to a treatment as 
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usual. This is the aim of the present research. It will determine the effectiveness of a brief 
psychiatric intervention and detail its psychobiological underpinnings of change.  
A methodological problem and a possible solution  
Earlier studies focusing on mechanisms of change in treatments for BPD fall into two 
major categories, neglecting a possible methodological integration explaining 
psychobiological change. Some studies used psychotherapy process research, describing 
change on patient central variables in-session (27-29) favoring external clinical validity, but 
remaining sensitive to the session-internal influences by the patient-therapist interaction (i.e., 
therapist responsiveness; (30). Other studies used biological assessments of change where the 
changing variable was observed on neurobiological activation to the exposed standardized 
stimuli (31, 32) – favoring internal validity, but neglecting the idiographic content so central 
to understand change in psychotherapy.  
In order to address these methodological problems, we suggest researchers should 
carefully integrate methods from psychotherapy process research with neurofunctional 
methods, by taking into account the individual’s subjective experience as anchor – 
substantiated in the form of individualized stimuli in the experiment – in the assessment of the 
mechanisms (12, 33). This is only meaningful when the design controls for a number of 
manipulation checks (see under Methods). Such an integrated experimental design goes 
beyond the systematic assessment of the therapy process, as described by our earlier studies 
(28, 34, 35), in addition, it becomes possible to relate aspects of the patient’s subjective 
experience to the neurobehavioral correlates of change (see also the discussion by Tashiro et 
al., 2006, and Kramer, 2019 (12, 36)).  
Mechanisms of change in treatments for borderline personality disorder 
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Here below, we will focus on two potential mechanisms of change which are among 
the most potent so far, and embed them within our integrative conception of mechanisms of 
change: (1) emotion processing, (2) socio-cognitive processing. 
Emotion processing: change in affect-meaning states related to self-criticism 
Change in emotion processing is central for psychotherapy in patients with BPD (37). 
Greenberg and colleague (2006) have differentiated between, among others, emotion 
regulation and emotion transformation (38). With regard to emotion regulation over the 
course of psychotherapy, Neacsiu and colleagues (2010) showed that the acquisition of 
specific coping skills strategies, aiming at more efficient emotion regulation functioned as 
mediator of change in DBT (39). These findings were in line with results found in a pilot 
fMRI study: Schnell and colleague (2007) investigated cognitive reappraisal over the course 
of inpatient DBT for N = 6 patients with BPD (31). The authors showed a decrease in 
activation over the course of therapy on the levels of the right ACC, the temporal and 
posterior cingulated cortex and the left insula (31). Using a previously validated procedure of 
cognitive reappraisal (40), Schmitt and colleagues (2016) confirmed parts of these results on a 
sample of patients with BPD (N = 32 patients) undergoing DBT and showed an enhanced 
neural connectivity between ventro-lateral pre-frontal cortex areas and the amygdala (32), 
consistent with the neuropathological model put forward by New and colleagues (2007)(41). 
Comparable results were obtained on N = 11 patients with BPD undergoing DBT, compared 
with N = 11 healthy controls: a decreased amygdalar reactivity was found after DBT (42, 43). 
Consistent results were found for change in distraction as emotion regulation strategy (44) and 
change in pain-mediated emotion regulation (45). Perez and colleagues (2015) showed 
consistent effects speaking in favor of enhanced fronto-limbic connectivity after a one-year 
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long Transference-Focused Psychotherapy (TFP) for N = 10 patients with BPD (46). Taken 
together, these results suggest improved emotion regulation capacities after therapy for 
patients with BPD, but more research integrated within a larger theoretical framework is 
necessary. 
In addition to the regulation perspective on emotion, we define emotion 
transformation as the change process by which emotions unfold and change over time from 
the least productive to the most productive, the latter being underpinned my increased 
meaning making (47). It was shown that this process relates to healthy functioning and good 
psychotherapy-outcome (34), in particular the flexibility of emotional experiences (47). The 
relevance of this dynamic conception of emotion processing for BPD was supported in terms 
of change in anger processing (48) and in terms of change in undifferentiated global distress 
(27). It was shown to also be of relevance in narcissistic and histrionic PDs (49, 51). 
This transformation conception may explain the resolution of harsh self-criticism, a 
central clinical feature of BPD (48, 52-54). Whelton and Greenberg (2005) proposed a 
paradigm of studying emotion transformation related to self-criticism using the empty chair 
dialogue. Patients criticized themselves in a structured assessment procedure using 
imaginative and emotion-eliciting enactment tasks. It appeared that the depressive persons 
presented more self-contemptuousness in their self-criticism, compared to controls and 
presented with higher levels of shame, sadness and emotional collapse, along with less pride 
(55). This study was on N = 45 undergraduates presenting with and without anger problems, 
using the same paradigm (49). What differentiated the two groups was the presence of self-
contemptuousness, t(1, 43) = 1.91, p < .05) associated with the self-criticism, along with the 
absence of the existential need in the anger-prone individuals. This means that for anger-prone 
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participants – which share this clinical feature to some extent with BPD –, self-criticism is 
particularly harmful to the emotion transformation when associated with self-
contemptuousness. We may therefore assume that decrease in self-contemptuousness – and 
possibly increase in its antidote self-compassion – and increase in emotion flexibility are 
markers of productive change in treatment. 
Emotion transformation related to self-criticism is underpinned by biological changes. 
Using standardized stimuli, Longe et al. (2010) showed in a female student sample (N = 17) a 
BOLD activation (intra-subject comparison to a neutral condition at the level p < .05 
corrected) in the left pre-frontal cortex (PFC; BA 45), in the lateral orbito-frontal cortex 
(OFC; BA 47), in the left dorsolateral PFC (BA 9), inferior and middle temporal gyrus (BA 
20 & 21, including lingual gyrus, BA 19) (56). The hyperactivity in pre- and orbito-frontal 
regions associated with self-criticism in this study was interpreted as linked with the 
inhibitory behavior known to be associated with activation of the lateral PFC (57). Brain 
activity in the striatum was associated with self-punishing emotions of self-criticism (55), 
such as shame, anger about the self and self-contemptuousness (35). In addition, some regions 
of the insula-basal ganglia networks are known to be associated with disgust processing (58). 
In an fMRI study using individualized self-critical stimuli (which were previously selected 
based on a large set of words), Doerig and colleagues (2013) showed bilateral insula 
activation, along with activations in left hippocampus and amygdalar formations, interpreted 
as regions recruited in emotion processing of self-critical stimuli (59). More research is 
needed to understand change in self-contemptuousness and its neuronal substrates over the 
course of treatment for BPD, when an individualized measurement method is applied. 
Change in socio-cognitive processing: integrating “hot” interpersonal information 
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Change in the patient’s socio-cognitive, or mentalizing capacities is a discussed 
putative mechanism of change in the treatment of BPD (53, 60, 61). Levy and colleagues 
(2006) examined change in three forms of psychotherapy for BPD – TFP, DBT and 
supportive therapy – and found that only TFP was associated with the increase of mentalizing 
functions, along with development of more secure attachment patterns for some patients in 
this group (29). Consistent results were presented by Fischer-Kern and colleagues (62) (see 
also de Meulemeester et al (63); Maillard et al., (64)).  Other research has underlined the 
moderating factor of mentalizing capacities for outcome for different categories of PD (65, 
66). To our knowledge, no studies have shown mediation for changes in socio-cognitive 
processing in treatments for BPD. 
 One method to investigate the core interpersonal contents related with attachment 
figures (i.e., “hot” stimuli), again formulated from an individualized perspective, is the core 
conflictual relationship theme (CCRT;(67)). A CCRT is a formulation composed by a 
patient's wish (e.g., to be close, to be treated harshly), the anticipated response of the other/the 
object (e.g., to facilitate one's independence, to be harsh) and the response of the self (e.g., to 
feel understood, to be frustrated). According to Luborsky (1998), pervasiveness of a CCRT is 
the degree of generality of a theme across specific relationship episodes and specific 
interactions(67). In patients with BPD, one may identify a central theme for each person 
which is present in more than 60% of the specific relationship episodes (68, 69). After 
treatment, it is expected that pervasiveness related to the core theme decreases. Luborsky 
(1998) demonstrated for N = 33 patients undergoing psychodynamic psychotherapy – 
although not patients with BPD –, a pre-post decrease of pervasiveness over time (F(1, 32) = 
7.4, p < .01) which was particularly strong for the category of the negative response of the 
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self. This decrease correlated with symptom change at the end of treatment (67). Therapy 
studies on patients with BPD are needed, to test the role of decrease in CCRT pervasiveness 
over time. 
As such, an emerging field of research focuses on the explanatory roles of (a) the 
patient’s emotion processing, (b) the patient’s capacities of socio-cognitive processing, for 
treatment effects related with PDs. We think that the most promising assessments rely on an 
integration between idiographic and nomothetic assessment procedures. 
Objectives {7} 
1. (Outcome) A 10-session BPD-specific guideline-based treatment produces more 
reduction in specific borderline symptoms than a non-specific treatment as usual (TAU). 2. 
(Global change) A 10-session BPD-specific treatment presents pre-post change in socio-
cognitive processing (SCP) and emotion processing (EP), which is not the case in the 
TAU. 3. (Treatment response) SCP and EP change more in treatment responders, 
compared to non-responders (across conditions). 4. (Mediation) The changes in these 
potential mechanisms of change will function as mediators of symptom decrease (between 
intake, discharge and follow-up; the latter will be used to disentangle potential time 
confounds). Change is operationalized on behavioral and neurofunctional (by controlling 
for the corresponding behavioral/idiographic information) levels. For post-therapy EP, we 
expect a greater emotional variability when dealing with individualized self-criticism, 
along with lesser self-contemptuousness, compared with pre. It is expected that post-
therapy neuronal activations are lower in a EP network involving areas in the PFC, the 
striatum and the insula-basal ganglia (58, 59), when compared with pre. For post-therapy 
SCP, we expect a lower CCRT pervasiveness, when compared with pre, and we expect that 
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post-therapy neurofunctional activations are lower in regions associated with the theory of 
mind (i.e., anterior cingulate, precuneus, inferior and middle frontal gyri and inferior 
parietal lobes; (70-72), compared with pre.  
Trial design {8} 
 The present study is planned as a randomized controlled treatment trial, involving a 
guideline-based psychiatric treatment (General Psychiatric Management; GPM; (20)) for 
BPD, over the course of a 4-month-plus-12-month-follow-up treatment program, in 
comparison with a 4-month treatment as usual, by focusing on the underlying mechanisms of 
change. The outcome part is a superiority trial, while the mechanisms part focuses on 
controlled comparison of processes of change.  
Methods: Participants, interventions, outcomes 
Study setting {9} 
The trial takes place in the context of Lausanne University Hospital and the University 
of Lausanne, Switzerland. 
Ethical clearance 
With respect to the submitted project on the SwissEthics plateform, the competent 
Canton de Vaud Ethics Committee, has approved the study (2017-02167). The study is 
registered (NCT0317818). In keeping with the established, and approved, Data Management 
Plan, only anonymous data will be kept in the file. All video raw data, where the patient may 
be identified, as well as fMRI data, will be stored separately from patient identifiers and from 
the main dataset. 
Eligibility criteria {10} 
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Patients with Borderline Personality Disorder (BPD) according to Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (73) mastering French to a sufficient 
extent will be included. Rate of comorbidity is expected to be high. All patients accepting the 
study by informed written consent will be included in the outcome and mechanisms parts of 
the study; a sub-group of patients with additional inclusions criteria (female, younger than 45 
years, right-handed, no or stable medication and absence of formal counter-indication on the 
security check) will be included in the fMRI part of the study. 
Patients with neurocognitive disorder, psychosis and bipolar disorder I will be 
excluded from the trial. In order to ensure generalizability of the results to a wide variety of 
clinical settings, no other exclusion criteria will be applied. 
Who will take informed consent? {26a} 
After the patient makes a request for treatment at the Department of Psychiatry, 
University of Lausanne, for problems related with BPD, the patient meets with a researcher 
who explains to him/her the study and informs him/her about the randomization and the 
assessment schedule. On the consent form, participants will be asked if they agree their data 
be used should they choose to withdraw from the trial. Participants will also be asked for 
permission for the research team to share relevant data with people from the Universities 
taking part in the research or from regulatory authorities. 
Additional consent  provisions for collection and use of participant data and biological 
specimen {26b} 
This trial does not involve collecting biological specimens for storage {26b; 33}. The 
relevant consent form can be obtained from the corresponding author upon request {32}. 
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Interventions 
Explanation for the choice of comparators {6b} 
 In order to test the hypotheses, a brief version of Good Psychiatric Management is 
compared with a brief version of Treatment of Usual. This is in keeping with standard 
methodological recommendations in the study of effectiveness of psychotherapeutic 
interventions. 
Intervention description {11a} 
Brief treatment encompasses the communication about diagnoses, problem areas, 
anamnesis, the work on treatment focus, objectives and motivation, the treatment of 
treatment-interfering problems and the elaboration of interpretations related with the core 
concept of interpersonal hypersensitivity, according to the principles of General Psychiatric 
Management for BPD (GPM; (20, 75-77). For the TAU, 10 therapists will intervene using 
non-specific crisis management as usual (minimal ethical assessment and contact with the 
patient according the local directives, ensuring safety management). 
Criteria for discontinuing or modifying allocated interventions {11b} 
Should a participant request discontinuation of the intervention, the study therapist 
will use this as criteria for discontinuing and modifying the allocated intervention. 
Strategies to improve adherence to interventions {11c} 
Therapist adherence to the protocol will be self-assessed by therapist using 
Gunderson’s (2016) questionnaire for adherence to good psychiatric management principles, 
to be filled in after each treatment. 
Relevant concomitant care permitted or prohibited during the trial {11d} 
Relevant concomitant care was permitted during the trial, and was recorded. 
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Provisions for post-trial care {30} 
The Data Management Plan (see below) outlines procedures in case of adverse events 
in the context of the trial which includes provision, if needed of post-trial care in case of 
harm. 
Outcomes {12} 
The main outcome measure  is the Zanarini Rating Scale for Borderline Personality 
Disorder (ZAN-BPD (78)). ZAN-BPD is a continuous hetero-administered measure assessing 
the nine criteria outlined in DSM-5, on a continuous Likert-type scale ranging from 0 to 4. As 
such, it yields a total theoretical score of 36. A comprehensive validation study has shown its 
reliability, validity and sensitivity to change (78).  
Emotion processing related to self-criticism will be assessed using the self-criticism 
task. This task involves two main steps. (1) Conduct of a two-chair dialogue on self-criticism, 
an individualized and therefore particularly emotion-arousing procedure ((35, 55, 79) and 
observer’s process rating of the patient’s emotions using the Classification of Affective 
Meaning States (CAMS;(80); see also (34, 47)) with the aim of extracting n = 20 
individualized self-critical words for each patient at each assessment point. Increase in 
emotion flexibility (i.e., more different emotion categories as a reaction to the self-criticism) 
over time, along with a decrease in self-contemptuousness associated with the self-criticism 
over time, are indicators of productive change. (2) Test, one week later, of neural correlates of 
the processing related to the n = 20 individualized self-critical words (extracted from step 1), 
in comparison with a set of n = 20 negative emotional (81), n = 20 positive emotional (81), n 
= 20 neutral words and n = 20 non-words (symbols; in total N = 100 words; presented in a 
random order). Self-reported emotional arousal (on SAM) and self-esteem (on SSES), along 
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with observer-reported fear/shame (on CAMS) reaction, will be measured as manipulation 
checks for step 1; SAM assessment will be done for each stimulus presented in the scanner. 
This task was empirically tested in a non-published pilot study: for n = 5 individuals, we 
showed for the individualized words higher subjective arousal levels than for the standardized 
negative words, along with comparable neurofunctional activations. 
 Change in socio-cognitive processing of interpersonal patterns will be assessed using 
two independent tasks, one behavioral, and the other fMRI. The behavioral task involves the 
conduct of a structured interview using the Relationship Anecdote Paradigm (67) and based 
on this video-taped structured material, observer’s process rating of the patient narrative using 
the CCRT (67-69) with the aim of comparing its pervasiveness pre-post-follow-up (see Figure 
1). Decrease in CCRT pervasiveness is an indicator of productive change. The fMRI task 
involves the appreciation of humoristic stimuli measuring the patient’s theory of mind; this 
task has previously been validated for BPD ((70); see for the validation of the stimuli (82, 
83)). It involves the processing and understanding of three sets of stimuli, presented in a 
pseudo-random order: (1) ToM (theory of mind): visual jokes requiring attributing false 
mental states to the protagonists presented in the cartoons (30 stimuli), (2) PUN (visual puns): 
visual puns, i.e., cartoons that are based on visual similarities, not requiring attributing false 
mental states (30 stimuli) and (3) a non-humorous control condition with incongruent visual 
information (30 stimuli, in total N = 90). Manipulation checks involve the assessment of the 
understanding of each joke. Decrease in activation of ToM network over time is an indicator 
of productive change.  
 The remaining assessments concern secondary outcomes and include the Outcome 
Questionnaire-45 (84) which is a self-report questionnaire comprising 45 items aiming at 
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assessing psychotherapeutic results, including a global score and three sub-scale scores: 
symptomatic level, interpersonal relationships and social role. It has been translated and 
validated in French (85). The Borderline Symptom List (BSL-23, (86)) is a self-report 
questionnaire assessing the BPD symptomatology using 23 items ; it represents a short 
version of the more extensive Borderline Symptom List (87) for which excellent psychometric 
properties were reported. Similar results were found for the short version used in this study 
(86).The French version has shown comparable validity coefficients (88). The Inventory of 
Interpersonal Problems (IIP, (89); French translation by Stigler) is a self-report questionnaire 
assessing interpersonal patterns on several dimensions, such as affirmation, affiliation, 
submission, intimacy, responsibility and control. In total, this questionnaire comprises 64 
items. Spielberger State-Trait Anger Inventory (STAXI-2;(90)) is a self-report questionnaire 
on trait and state anger, using 44 items. The French validation and adaptation was carried out 
by Borteyrou, Bouchon-Schweitzer and Spielberger (91). The Difficulties in Emotion 
Regulation Scale (DERS; (92)) is a self-report questionnaire assessing the quality of emotion 
regulation using 36 items. The French translation and validation of this instrument yielded 
satisfactory factor structure on a student sample (93). As measure of the therapeutic alliance, 
the Working Alliance Inventory (WAI; (94); French validation (95)) will be given after each 
session; the therapeutic alliance will be introduced as moderator where appropriate. At intake, 
reliable psychiatric diagnoses (using SCID-5-CV and SCID-5-PD by American Psychiatric 
Association), childhood trauma (Childhood Trauma Questionnaire; (96); French version(97)), 
rejection sensitivity (Rejection Sensitivity Questionnaire-Adult; (98)) and the level of 
intelligence (NART reading test, French version (99)) will be assessed.  
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Manipulation checks  will be introduced by using self-report questionnaires of arousal 
(Self-Assessment Manikin; SAM; (100)), self-esteem (State Self-Esteem Scale; SSES;(101)) 
and vividness (Vividness of Visual Imagery Questionnaire; VVIQ; (102, 103)). 
Participant timeline {13} 
Assessments take place at intake, 2 months and discharge, plus at follow-up after 12 
months. At follow-up, the participants will be contacted by the research team;  see {18b}.  
Importantly, any participant who dropped out of treatment will still be contacted for research 
assessments and follow-ups.  
Sample size {14} 
Based on a power-analysis (presumed power .819, for 2 concomitant mechanisms, d = 
0.60; two-tailed alpha = .05; 30% drop-out), N = 80 patients presenting with BPD are planned 
to be recruited for the present study at the Department of Psychiatry, University of Lausanne, 
Switzerland. In total, N = 10 therapists (psychiatrists or psychologists) participate in the study 
for the GPM treatment; they have at least 6 hours of specific training in psychiatric treatment 
for BPD (74), in addition to training in psychotherapy according to Federal regulations. 
Recruitment {15} 
The recruitment takes place at the Department of Psychiatry, University of Lausanne,  
Switzerland, at a specialized clinic for the treatment of borderline  personality disorder. The 
current patient flow will guarantee the recruitment in the protocol. Patients are paid CHF 70.- 
for full participation in an assessment point. 
Assignment of interventions: allocation 
Sequence generation {16a} 
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 A system involving computer-generated random numbers (block-randomization in 
blocks of 10) was used at the outset and put into sealed envelopes. The latter are opened by 
the researcher upon patient inclusion. No apriori stratification is performed. 
Concealment mechanism {16b} 
The sequence is concealed by sealed envelopes which were created by a trial-
independent researcher. 
Implementation{16c} 
 The allocation sequence is generated by the computer, the concealment by an 
independent researcher. Then the study researchers enroll the participants and assign 
participants  to interventions,  after the opening of the sealed envelope. 
Assignment of interventions: Blinding 
Who will be blinded {17a} 
The (outcome and mechanisms) assessors and data analysts will be blind to the 
condition, but the patients nor the therapist will not be. In order to control for biases, assessors 
will be polled at the end of the study with regard to each patient’s condition. 
Procedure for unblinding if needed {17b} 
The competent Ethics Committee can request audits at any moment in time and the 
primary investigator and his team will follow its instructions. Audit may include to disclose, 
in a restricted fashion and only if deemed necessary, personal data related to participants to 
the Ethics Committee. 
Data collection and management 
Plans for assessment and collection of outcomes {18a} 
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All relevant information related to the reliability and validity of the outcome measures 
are provided under assessments {12}. All interviewers, assessors and raters are extensively 
trained in the relevant assessment procedures, and reliability checks are done continuously. 
All data are collected in a secured online system which assures privacy protection and data 
integrity, as described in the Data Management Plan (see below). 
Plans to promote participant retention and complete follow-up {18b} 
At follow-up, the participants will be contacted by the research team.  Importantly, any 
participant who dropped out of treatment will still be invited for research assessments and 
follow-ups. 
Data management {19} 
According to the accepted Data Management Plan, data will be entered into RedCap 
on a secured space on the University server. This program allows full accountability of data 
management, and should problems arise, standard procedures are in place. All details are 
found in the Data Management Plan, which can be obtained from the primary investigator 
upon request. 
Confidentiality {27} 
Data safety is guaranteed by the system’s security check and no formal data 
monitoring committee is requested. Participants’ personal information will be stored at a 
separate, locked, place at the Department of Psychiatry. No personal information will be 
revealed neither before, during nor after the trial (except for the case of audit by the 
competent Ethics Committee; plans to give access to protocol, participant level-data and 
statistical code are described in the Data Management Plan, see {31c}).  
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Plans for collection, laboratory evaluation and storage of biological specimens for 
genetic or molecular analysis in this trial/future use {33} 
 
This trial does not involve collecting biological specimens for storage. 
Statistical methods 
Statistical methods  for primary and secondary outcomes {20a} 
  For the behavioral assessments and all outcomes, we will conduct intent-to-treat and 
completer analyses for all variables (hypothesis 1: outcome, defined as residual gains at 
discharge). We will use multilevel modeling (104) where appropriate, for hypotheses 2 and 3 
(global change and treatment response). For hypothesis 4 (mediation), we will conduct a 
mediation analysis for both potential mechanisms of change (105). Raw and composite scores 
for outcome and all mechanisms of change indexes will be used, by controlling for the 
corresponding fMRI data from the same assessment point. Composite scores involve for EP 
combining pre-post change in contemptuousness with change in neuronal regions of interest 
for individualized self-criticism. For SCP, this involves combining pre-post change in CCRT 
pervasiveness with change in neuronal regions of interest for theory of mind.  
  Therapist effects will be controlled for in the three-level HLM (106). All indexes (i.e., 
behavioral and fMRI) of the patient groups (N = 80) at intake will be rigorously compared 
with the indexes found for the healthy control (N = 20); we expect systematic between-group 
differences, in the context of a control analysis. Statistical treatment packages HLM7 and 
SPSS23 will be used for the analyses of the behavioral indexes. 
For the fMRI assessments, we will use the methodology of blood-oxygen-level-
dependant (BOLD) imaging followed by standard data processing and statistical analysis in 
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the framework of SPM12. The fMRI data will be acquired on a Siemens Prisma 3T (64-
channel head coil using a 2D EPI sequence). The acquisition parameters will be as follows: 3 
x 3 x 3 mm3: TE =30 ms, slice TR = 66 ms, 30 slices, flip angle = 90°. The structural MRI 
data consists of T1-weighted MPRAGE images (TR = 2000 ms; TI = 920 ms; α = 9°; BW = 
250 Hz / pixel; readout in inferior-superior direction; FoV = 256 x 232 mm; 176 slices) at 1 
mm resolution. All data pre-processing will be performed using the Statistical Parametric 
Mapping software (SPM12; Wellcome Trust Centre for Neuroimaging, 
shttp://www.fil.ion.ucl.ac.uk/spm/) running under Matlab 7.13 (The MathWorks, Inc., Natick, 
MA, USA). EPI images will be realigned to the subject’s average image across trials 
(corrected for spatial distortions using the SPM fieldmap tools). The parameters of 
registration to standardized MNI space will be calculated on the anatomical image and the 
default settings of the “unified segmentation” framework followed by the diffeomorphic 
registration algorithm DARTEL (107, 108). The spatial registration parameters will be 
applied to the functional time-series co-registered to the corresponding individual’s 
anatomical scan. Prior to statistical analysis, we will apply a spatial smoothing with a 
Gaussian kernel of 8 mm full-width-at-half-maximum. All statistical analyses will be 
performed using the default settings in SPM12. The statistical analysis at subject-specific 
level will be performed using the General Linear Model (GLM) after convolving the event 
onsets with a canonical hemodynamic response function (109). Both time-points will be 
modeled as two separate sessions within the design matrices. For the EP task, we will 
calculate at the subject level the interaction between WORDS (self-critical vs standard 
negative words; the non-words and the negative words will be excluded from the analyses, but 
used as control variables to ensure cognitive appropriateness) and TIME (time point 1 vs time 
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point 2) using symbols as baseline. For the SCP task, the subject-level differential t-contrast 
will test the interaction between ToM, PUN and time point (the control stimuli will be 
excluded from the data analysis, but will serve as control for cognitive appropriateness). For 
both tasks, we will use a one-sample t-test along with the outcomes and arousal changes 
associated with treatment as regressors for the group-level analyses. The differential contrasts 
at the group level will test the positive and negative correlation between the interaction at the 
subject-specific level and BOLD signal changes. Where appropriate, we will control for the 
corresponding behavioural data from the same assessment point. 
Interim analyses {21b} 
  No formal stopping rule of the trial is necessary, as the time limit of the recruitment 
phase (due to funding) will decide upon the stopping of the recruitment. In addition, we do not 
anticipate any specific problems that are detrimental to the participants. 
Methods for additional analyses (e.g., sub-group analyses) {20b} 
  No additional sub-group analyses will be performed. 
Methods in analysis to handle protocol non-adherence and any statistical methods to 
handle missing data {20c} 
Treatments with low adherence scores will still be included in the trial, but the level of 
adherence on the named scale will be included as controlled variable on the level of the 
statistical analyses. For missing values, we will use classical methods of multiple imputations. 
Plans to give access to the full protocol, participant level-data and statistical code {31c} 
Plans to give access to protocol, participant level-data and statistical code are 
described in the Data Management Plan.  
Oversight and monitoring 
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Composition of the coordinating centre and trial steering committee {5d} 
The coordinating centre of this RCT is directed by the primary investigator and all co-
authors meet at least once a month to oversee advancement of the project; this is also the case 
for the Trial Steering Committee (TSC).  There are three sub-groups within this TSC: a) 
clinical sub-group (i.e., therapists and supervisors), b) research sub-group (i.e., clinical 
researchers), and c) fMRI specialists and researchers (i.e., fMRI researchers). There is no 
specific group related to tasks of the Stakeholder and Public Involvement Group (SPIG). 
Ethics Committee do not meet with regard to this trial, except for specific audits or upon 
request by the Sponsor or the primary investigator{23}. 
Composition of the data monitoring committee, its role and reporting structure {21a} 
Given the structure explained under {5d} and the transparent handling of the 
assessments, it is not necessary to have an additional data monitoring committee. 
Adverse event reporting and harms {22} 
The same Data Management Plan outlines procedures in case of adverse events in the 
context of the trial which includes provision, if needed of post-trial care in case of harm {30}. 
In particular, no serious Adverse Events (SAE) are anticipated as a result from the trial or the 
intervention. Should there be any, they will be reported immediately as required in terms of 
expectedness, seriousness, severity and causality. 
Frequency and plans for auditing trial conduct {23} 
Ethics Committee do not meet with regard to this trial, except for specific audits or 
upon request by the Sponsor or the primary investigator. 
Plans for communicating important protocol amendments to relevant parties (e.g., trial 
participants, ethical committees){25} 
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The trial was approved by the competent ethics committee (see above) and potential 
amendments will have to be approved by the same, and be communicated to publishing 
journals. 
Dissemination plans {31a} 
Publications of the results will be encouraged to all relevant groups (i.e., scientific 
publication, communication at conferences, communication with stakeholders, patients and 
families). 
Feasibility: results from the pilot study 
We demonstrated feasibility of the pre-post design (50). We demonstrated for N = 8 
medication-free right-handed female patients with BPD undergoing a 10-session psychiatric 
treatment that hypotheses 1 and 2 may be confirmed (due to the small sample size, the 
analyses for hypotheses 3 and 4 were not tested). The behavioral pre-post treatment outcome 
effect sizes ranged between d = 0.41 (for OQ-45) and d = 0.51 (for BSL-23). We observed 
arousal increase within session of the two-chair dialogue (d = 0.36), paralleled by a large 
decrease in peak arousal between pre- and post-treatment (d = 0.80). In the EP task, we 
demonstrated treatment associated trends for neural activity reduction in the associative parts 
of putamen when exposed to the individual’s own self-critical words. The exposure to ToM 
stimuli revealed trends for treatment related neural activity modulation in the OFC, ACC and 
NAcc, and the medio-dorsal nucleus of the thalamus. Neural activity (i.e., in the precuneus, 
left amygdala) related with the behavioral changes in arousal, but remained independent from 
outcome, whereas change in arousal was related with symptom reduction. Feasibility of the 
trial and relevance of the pre-post hypotheses are therefore demonstrated, and represents 
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therefore a strong justification for the conduct of the RCT. In addition, effects found were the 
basis for the computation of the effect sizes for the trial {14}. 
Discussion 
Borderline Personality Disorder is among the most debilitating and lethal mental 
disorders. Each year, millions are spent on direct and indirect costs related to this disorder and 
thousands of patients complete suicide, profoundly impacting the lives of those left behind. 
Effective treatments of BPD exist, but remain difficult to disseminate. Brief psychiatric 
treatment is cost-effective and may produce, to some extend, similar effects than a structured 
psychotherapy program, at least may represent a promising initial treatment in a stepped-care 
approach: we think that its implementation should therefore be a major priority in the health 
care system. This is the first study testing the effectiveness of such brief guideline-based 
psychiatric treatment (compared to a treatment as usual) and its underlying mechanisms of 
change. The latter will be done by taking into account the individual’s subjective perspective 
in the assessment. The integrated methodology optimally compensates for respective 
limitations of psychotherapy process and neurofunctional assessments, making it the 
scientifically most precise, and the clinically and ecologically most relevant approach, to the 
measurement of mechanisms of change in treatment research. Therefore, this study does not 
only contribute to the understanding of the effects of treatment as a whole, but also should 
help render even more effective treatments for BPD by a clinically relevant understanding of 
how change is produced through psychological treatment. 
Trial status 
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This study is currently ongoing and is not completed (protocol version number 2 from 
February 9th, 2018; start of recruitment December 1st, 2018; projected end of recruitment August 
31st, 2021). 
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